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Background: The adipokine leptin and its receptor are expressed in the heart, and leptin has been shown to
promote cardiomyocyte hypertrophy in vitro. Obesity is associated with hyperleptinemia and hypothalamic leptin
resistance as well as an increased risk to develop cardiac hypertrophy and heart failure. However, the role of cardiac
leptin signaling in mediating the cardiomyopathy associated with increased body weight is unclear, in particular,
whether it develops subsequently to cardiac leptin resistance or overactivation of hypertrophic signaling pathways
via elevated leptin levels.
Methods: The cardiac phenotype of high-fat diet (HFD)-induced obese wildtype (WT) mice was examined and
compared to age-matched genetically obese leptin receptor (LepR)-deficient (LepRdb/db) or lean WT mice. To study
the role of leptin-mediated STAT3 activation during obesity-induced cardiac remodeling, mice in which tyrosine
residue 1138 within LepR had been replaced with a serine (LepRS1138) were also analyzed.
Results: Obesity was associated with hyperleptinemia and elevated cardiac leptin expression in both diet-induced
and genetically obese mice. Enhanced LepR and STAT3 phosphorylation levels were detected in hearts of obese
WT mice, but not in those with LepR mutations. Moreover, exogenous leptin continued to induce cardiac STAT3
activation in diet-induced obese mice. Although echocardiography revealed signs of cardiac hypertrophy in all
obese mice, the increase in left ventricular (LV) mass and diameter was significantly more pronounced in LepRS1138
animals. LepRS1138 mice also exhibited an increased activation of signaling proteins downstream of LepR, including
Jak2 (1.8-fold), Src kinase (1.7-fold), protein kinase B (1.3-fold) or C (1.6-fold). Histological analysis of hearts revealed
that the inability of leptin to activate STAT3 in LepRdb/db and LepRS1138 mice was associated with reduced cardiac
angiogenesis as well as increased apoptosis and fibrosis.
Conclusions: Our findings suggest that hearts from obese mice continue to respond to elevated circulating or
cardiac leptin, which may mediate cardioprotection via LepR-induced STAT3 activation, whereas signals distinct
from LepR-Tyr1138 promote cardiac hypertrophy. On the other hand, the presence of cardiac hypertrophy in obese
mice with complete LepR signal disruption indicates that additional pathways also play a role.
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Obesity is frequently associated with elevated circulating
leptin levels [1] and an increased risk to develop cardiac
hypertrophy [2,3] or heart failure [4]. Clinical studies dem-
onstrated a positive correlation between serum leptin
levels and left ventricular (LV) mass or wall thickness
[5,6], independent of blood pressure levels, suggesting a
direct role for leptin in the pathogenesis of obesity-
associated cardiomyopathy. Furthermore, leptin was
shown to promote hypertrophy of isolated rat or human
ventricular cardiomyocytes [7,8], and this effect could be
prevented using neutralizing antibodies [9].
Cardiac hypertrophy also develops in obese rodents fed
high-fat diet (HFD) [10,11], and studies in mice with (func-
tional) leptin deficiency suggested that the cardiac hyper-
trophy developing in states of chronic hyperleptinemia may
result from the inability to transduce anti-hypertrophic
and/or cardioprotective effects of the adipokine [12,13].
While the effects of leptin on cell shortening and intracel-
lular Ca2+ transients were found to be abrogated in cardio-
myocytes isolated from HFD-fed obese rats [14], others
reported a preserved signal transduction in response to lep-
tin in hyperleptinemic obese mice [15,16] or rats [17].
Thus, the role of the adipokine in mediating cardiac hyper-
trophy, in particular in the presence of elevated systemic
leptin levels, and the possible existence of a cardiac leptin
resistance in obesity remains unclear.
The leptin receptor (LepR) belongs to the family of cyto-
kine type I receptors known to signal via activation of
Janus kinase (Jak)-2 and signal transducer and activator of
transcription (STAT)-3 [18]. Analysis of cardiomyocytes
ex vivo revealed that leptin promotes hypertrophy via acti-
vation of p38 and p42/44 MAP kinases as well as protein
kinase B (Akt) [19,20]. On the other hand, it is unknown
whether STAT3 activation downstream of LepR is required
to transmit the cardiac effects of leptin and whether it may
be involved in mediating protective (i.e. anti-apoptotic,
anti-fibrotic or pro-angiogenic) signals, as previously
reported in mice with cardiomyocyte-specific STAT3
deletion [21,22].
In this study, we examined the cardiac phenotype of
diet-induced (i.e. with hypothalamic leptin resistance)
and genetically obese (i.e. with systemic leptin receptor
deficiency) hyperleptinemic mice, developing with age or
after continuous β-adrenergic stimulation. Moreover, we
determined the importance of leptin-mediated STAT3
activation for the development of cardiac hypertrophy in
obesity by analyzing mice with targeted mutation of the
STAT3 binding site within LepR.
Methods
Animals
C57Bl6/J leptin receptor-deficient db/db (LepRdb/db;
BKS.Cg Leprdb/Leprdb) mice and C57Bl6/J wildtype(WT) controls were obtained from Harlan Winkelmann,
Germany. Mice heterozygous mutant for the LepRS1138
allele (on the congenic B6.129/J background; 98- > 99%
homozygous for C57Bl/6; [23]) were obtained from Pro-
fessor Martin Myers (University of Michigan Medical
School, Ann Arbor, USA) and bred at the animal facility
of the University of Goettingen, Germany, to generate
homozygous mutant obese LepRS1138 mice. Age- and
gender-matched WT (LepR+/+) and heterozygous (LepRS/+)
littermates were used as controls. To induce obesity,
3 months-old mice were switched to high-fat diet (HFD;
D12451) for 4 months, while controls were maintained on
normal rodent chow (D12450B; both Research Diets Inc.).
The composition of both diets is shown in Additional
file 1: Table S1. To examine the cardiac response to
hypertrophic stimuli other than leptin, osmotic minipumps
(Alzet®; model 2002; Charles River Laboratories) were filled
with isoprenaline hydrochloride (Sigma; 20 mg/kg body
weight [BW] per day) and implanted for 14 days under the
dorsal skinfold of 2 months-old, 2% isoflurane anesthetized
mice. At the time of tissue harvest, mice were weighed
followed by intraperitoneal anesthesia with a mixture of 2%
xylazine (6 mg/kg BW) and 10% ketamine hydrochloride
(100 mg/kg BW), and blood was drawn by cardiac punc-
ture. Hearts were rapidly excised, the atria removed and
ventricles immediately processed for protein isolation or
cryoembedding, respectively. All animal care and experi-
mental procedures had been approved by the institutional
Animal Research Committee and complied with national
guidelines for the care and use of laboratory animals.Serum analysis
Freshly drawn blood was allowed to clot at room
temperature (RT) for 30 min, followed by centrifugation
for 10 min at 3,000 rpm. The supernatant was stored at -
80°C pending analysis of serum leptin levels using specific
enzyme-linked immunoassays (ELISA; R&D Systems).Echocardiography
Echocardiography was performed by a blinded examiner
at the day before tissue harvest in mice under 1.5%
isoflurane anesthesia using the VisualSonics Vevo 2100
system (Visualsonics) equipped with a 30 MHz center
frequency ultrasound transducer, as previously described
[24]. M-mode echocardiographical recordings were used
to determine the end-diastolic and end-systolic LV diam-
eter (EDD and ESD, respectively) and the ventricular
wall thickness (WTh), corresponding to the mean of the
anterior and posterior WTh. LV mass was calculated
using the formula: 1.055 × ([AWTh + EDD + PWTh]3 -
EDD3). Fractional shortening (FS) was calculated as
(EDD - ESD)/EDD × 100. B-mode echocardiography im-
ages were used to calculate the heart weight, using the
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Histology and immunohistochemistry
Histochemical analyses were performed on 5 μm-thick
frozen cross sections through the LV. For each mouse, 4
sections (approx. 500 μm apart) and 4 randomly selected
viewing fields (at 200-fold magnification) per section
were analyzed and findings averaged. Cardiac fibrosis
was determined after overnight incubation in Bouin’s
fixative followed by Masson’s trichrome (MTC) stain.
Monoclonal rat antibodies against mouse CD31 (Santa
Cruz Biotechnology) were used to detect endothelial
cells [24,25]. Their number was manually counted by a
person blinded to the mouse genotype and expressed per
mm2 or cardiomyocyte, respectively. Single cardiomyocytes
were visualized by incubation with fluorescein-labeled
wheat germ agglutinin (WGA; Molecular Probes), followed
by determination of the cardiomyocyte cross-sectional area
(CSA) using image analysis software (Image ProPlus). Per
cross section, at least 10 randomly selected cardiomyocytes
were evaluated and results averaged. Apoptosis was ana-
lyzed using the ‘In Situ Cell Death Detection kit’ (Roche).
Cell nuclei were visualized using 4′,6-diamidino-2-pheny-
lindole (DAPI; Sigma).
Immunoprecipitation and western blot analysis
Frozen whole heart tissue (after removal of both atria)
was pulverized on liquid nitrogen and resuspended in
500 μL lysis buffer (1% Triton-X 100, 150 mM NaCl,
50 mM TRIS, 5 mM EDTA, pH 7.5) containing fresh
protease (4 μg/mL of each aprotinin, leupeptin and
pepstatin A, 1 mM PMSF) and phosphatase (20 mM
NaF and 1 mM Na3VO4) inhibitors. After incubation for
20 min on ice, lysates were cleared by centrifugation at
13,000 rpm for 10 min at 4°C. Equal amounts (50 μg) of
protein were fractionated by SDS polyacrylamide gel
electrophoresis together with molecular weight stan-
dards and transferred to nitrocellulose membranes
(Protran®, Whatman). Membranes were blocked in 1%
bovine serum albumine (in TBS, containing 0.1%
Tween-20) prior to incubation with antibodies against
phosphorylated (p)-Akt (S473) and total Akt, p-Jak2
(Y1007/1008) and total Jak2, p-p38 (T180/Y182) and
total p38, p-p42/44 (T202/Y204) and total p42/44, p-Src
(Y416) and total Src, p-STAT3 (Y705) and total STAT3, or
p-PKC (pan), respectively (all Cell Signaling Technolo-
gies), or against leptin (R&D Systems) and GAPDH
(Biotrend), respectively. Protein bands were visualized
using HRP-conjugated secondary antibodies (Amersham
Biosciences), followed by detection with SuperSignal®
West Pico Substrate (Pierce). For the analysis of LepR
phosphorylation, 100 μg total heart tissue lysates were
immunoprecipitated under rotation at 4°C with 2 μg anti-LepR antibody (against an internal domain present in the
short and long isoforms of murine LepR; Santa Cruz
Biotechnology) plus 50 μL nProtein A Sepharose™ 4
Fast Flow beads (GE Healthcare) followed by detection
of phosphorylated tyrosines (p-Tyr [PY20]; Santa Cruz
Biotechnology) or LepR. For the analysis of STAT3
phosphorylation in response to acute elevations of cir-
culating leptin, mice were fasted overnight, injected
with recombinant murine leptin (1 mg/kg BW i.p.) and
hearts harvested 30 min later. Protein bands were
quantified by densitometry and results expressed as %
of total protein (after normalization for GAPDH
expression).
Statistical analysis
Quantitative data are presented as mean ± standard
error of the mean (SEM). Normal data distribution was
tested using the D’Agostino & Pearson omnibus normal-
ity test. When three or more groups were compared,
ANOVA was employed, if samples were normally dis-
tributed, or Kruskal-Wallis test, if not. For post-hoc com-
parisons, ANOVA was followed by Bonferroni’s and
Kruskal-Wallis by Dunn’s multiple comparison test. Dif-
ferences before and after isoprenaline infusion were
tested using Student’s t-test for paired means. Statistical
significance was assumed when P reached a value less
than 0.05. All statistical analyses were performed using
GraphPad PRISM software, version 4.01 (GraphPad
Software Inc).
Results
Clinical and experimental studies revealed that obesity is
associated with LV hypertrophy [10,11], an important risk
factor for the development of heart failure. As shown in
Tables 1 and 2, WT mice fed HFD for 4 months (WT +
HFD; mean body weight [BW], 44±1.9 g) to induce obesity
exhibited a non-significant trend towards an increased
mean heart weight, LV mass and WTh compared to age-
matched lean controls fed normal chow (BW, 29±1.0 g).
Marked LV hypertrophy was observed in 7 months-old
obese LepRdb/db mice (Table 1 and 2), consistent with a
previous report [12]. Longitudinal sections through hearts
of WT, WT + HFD and LepRdb/db mice are shown in
Figure 1A, representative M-mode echocardiography
recordings in Figure 1B and cardiac cross-sections
after WGA staining to delineate cardiomyocyte bor-
ders in Figure 1C. Of note, adiposity in mice with LepR
deficiency was more pronounced compared to age-
matched WT + HFD mice (Table 1; P < 0.001), in
which obesity develops as result of hypothalamic re-
sistance to chronically elevated leptin levels [26].
The presence of cardiac hypertrophy in LepR-deficient
and, to a lesser extent also in diet-induced obese mice,
suggests that it develops as a result of the heart’s
Table 1 Body, visceral fat and heart weights in 7 months-old mice
WT WT + HFD LepRS1138 LepRdb/db
n 25 12 30 30
body weight (g) 29 ± 1.0 44 ± 1.9*** 54 ± 1.1*** ### 55 ± 1.5*** ###
VAT (mg) 0.6 ± 0.1 1.7 ± 0.3* 3.3 ± 0.3*** ### 2.7 ± 0.2*** #
serum leptin (ng/mL) 12 ± 1.3 60 ± 6.0*** 67 ± 5.9*** §§§ 118 ± 6.8*** ###
heart weight (mg) 135 ± 3.6 147 ± 5.8 212 ± 11*** ### §§§ 151 ± 5.2
normalized heart weight (mg/mm TL) 7.5 ± 0.2 8.2 ± 0.3 12 ± 0.6*** ### §§§ 8.9 ± 0.2
normalized heart weight (mg/g BW) 4.8 ± 0.1 3.4 ± 0.2*** 3.9 ± 0.2*** §§§ 2.8 ± 0.1***
CSA (μm2) 148 ± 4.6 161 ± 6.4 183 ± 9.9** 165 ± 6.5
*P < 0.05, **P < 0.01 and ***P < 0.001 vs. WT mice; #P < 0.05 and ###P < 0.001 vs. WT mice fed HFD; §§§P < 0.001 for the difference between LepRS1138 and LepRdb/
db mice. Abbreviations: BW, body weight; CSA, cross-sectional area; HFD, high-fat diet; TL, tibia length; VAT, visceral adipose tissue.
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or cardiac (Figure 2A) leptin levels. In this regard, West-
ern blot analysis revealed increased levels of phosphory-
lated (p-) LepR (Figure 2B) and STAT3 (Figure 2C)
protein in hearts of HFD-induced obese mice (P < 0.05
vs. WT for both), whereas findings in LepRdb/db mice did
not differ from those in lean controls or were reduced
compared to those in WT + HFD mice (P < 0.05 for dif-
ferences in LepR phosphorylation). Moreover, both lean
and HFD-induced obese WT mice responded to a single
i.p. injection of recombinant murine leptin with a signifi-
cant increase in the cardiac STAT3 phosphorylation
(Figure 2D), suggesting a preserved cardiac leptin signal
transduction in hyperleptinemic, diet-induced obese mice.
To further study the role of leptin signaling in the de-
velopment of cardiac hypertrophy and also to determine,
whether the inability of leptin to activate STAT3 contrib-
utes to the cardiac maladaptation in obesity, we exam-
ined mice in which tyrosine (Tyr)1138 within LepR had
been replaced by a serine (LepRS1138). In these mice, lep-
tin cannot signal via STAT3, but continues to be able to
activate Jak2 and SH2 domain-containing adapter
proteins. Western blot analysis revealed that p-LepR
(Figure 2B) and p-STAT3 (Figure 2C) levels in hearts
of LepRS1138 mice did not significantly differ fromTable 2 Echocardiographic parameter in 7 months-old mice
WT WT + HF
n 25 12
heart rate (bpm) 463 ± 6.5 481 ± 6.7
WTh (mm) 0.70 ± 0.01 0.75 ± 0.
ESD (mm) 3.2 ± 0.1 3.5 ± 0.1
EDD (mm) 4.3 ± 0.1 4.5 ± 0.1
LVM (mg) 116 ± 4.2 132 ± 5.8
HW (mg) 118 ± 3.3 121 ± 3.6
FS (%) 26 ± 0.7 22 ± 0.8
*P < 0.05, **P < 0.01 and ***P < 0.001 vs. WT mice; #P < 0.05 and ###P < 0.001 vs. WT
LepRS1138 and LepRdb/db mice. Abbreviations: bpm, beats per minute; HW, calculate
fractional shortening; LVM, left ventricular mass; WTh, wall thickness.those in WT and LepRdb/db mice. Similar to mice with
complete LepR deficiency, lack of LepR-mediated
STAT3 activation resulted in severe adiposity, al-
though serum leptin levels were lower than those in
LepRdb/db mice (P < 0.001; Table 1). Interestingly,
obese LepRS1138 exhibited a more pronounced in-
crease in mean heart weights not only compared
to lean or diet-induced obese WT mice, but also com-
pared to LepRdb/db mice (P < 0.001 for all com-
parisons; Table 1), and differences persisted after
normalization for body weight (P < 0.001) or tibia
length (P < 0.001). Echocardiography confirmed in-
creased LV mass (P < 0.01) or heart weights (P <
0.001) in LepRS1138 mice compared to their LepRdb/db
counterparts (Table 2; please also see Figure 1A-C).
Moreover, hearts of LepRS1138 mice exhibited elevated
levels of phosphorylated Jak2 (P < 0.001 vs. WT;
Figure 3A), Src kinase (P < 0.05 vs. WT, WT + HFD
and LepRdb/db; Figure 3B), Akt (P < 0.001 vs. LepRdb/db;
Figure 3C), PKC (P < 0.05 vs. WT and LepRdb/db, P < 0.01
vs. WT + HFD; Figure 3D) and p38 MAPK (P < 0.01 vs.
LepRdb/db; Figure 3E), suggesting that an intact, Tyr1138-
independent LepR activation in the presence of elevated
leptin levels may have contributed to the pronounced car-
diac hypertrophy present in these mice. On the otherD LepRS1138 LepRdb/db
30 30
459 ± 10 460 ± 11
02 0.85 ± 0.02*** # 0.81 ± 0.02**
* 3.2 ± 0.1# §§ 3.0 ± 0.1* ###
4.6 ± 0.1** §§ 4.3 ± 0.03
166 ± 7.2*** # §§ 137 ± 5.5**
135 ± 4.6** §§§ 108 ± 2.0
31 ± 1.1* ### 31 ± 0.9** ###
mice fed HFD; §§P < 0.01 and §§§P < 0.001 for the difference between
d heart weight; EDD, end diastolic diameter; ESD, end systolic diameter; FS,
BA
C
WT WT+HFD LepRS1138 LepRdb/db
Figure 1 Cardiac phenotype of lean and obese WT, WT + HFD, LepRS1138 and LepRdb/db mice. (A) Representative H&E-stained longitudinal
sections through hearts of 7 months-old mice are shown. Magnification, ×10. (B) Representative M-mode echocardiographic recordings.
(C) Representative images of wheat germ agglutinin (WGA)-stained myocardial cross sections. The mean cardiomyocyte cross-sectional areas are
given in Table 1.
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cantly differ between the mouse groups (Figure 3F).
M-mode echocardiography also revealed significantly
increased enddiastolic LV diameters in LepRS1138 mice
(P < 0.01 vs. WT and LepRdb/db mice; Table 2; repre-
sentative findings are shown in Figure 1B), suggesting
that the observed (over-)activation of LepR signaling
together with the inability to induce STAT3 may result
in augmented hypertrophy and maladaptive cardiac re-
modeling. Of note, fractional shortening (FS) was not
significantly altered in HFD-induced obese WT mice
(P = n.s. vs. WT mice), but found to be increased inboth LepRdb/db (P < 0.01 vs. WT and P < 0.001 vs. WT +
HFD mice) and LepRS1138 mice (P < 0.05 vs. WT and P <
0.001 vs. WT + HFD mice). Histological analyses revealed
significantly reduced numbers of CD31-positive capillary
endothelial cells in LepRdb/db, and to a lesser extent also in
LepRS1138 mice (Figure 4A), whereas the number of
TUNEL-positive apoptotic cells (Figure 4B) and the fi-
brotic tissue area (Figure 4C) were found to be signifi-
cantly increased in hearts of both LepRS1138 and LepRdb/db
mice compared to lean and diet-induced obese WT mice.
To examine the specificity of leptin’s hypertrophic ac-
tion in obesity, the cardiac response of young, i.e.
Figure 2 Cardiac leptin expression and signal transduction in lean and obese mice. Protein was extracted from hearts of 7 months-old
mice (n = 8 per group) and analyzed for the expression of (A) leptin, (B) phosphorylated LepR (using immunoprecipitation of LepR, followed by
the detection of total phosphotyrosines and LepR) and (C) phosphorylated STAT3. (D) Cardiac STAT3 phosphorylation in response (30 min later)
to a single injection of recombinant murine leptin (1 mg/kg BW i.p.) was examined in WT (n = 4) and WT + HFD (n = 6) mice. Results are
expressed as -fold increase of controls (black bars) after normalization for total protein and GAPDH expression. The mean ± SEM as well as
representative Western blot results are shown. *P < 0.05 and **P < 0.01 vs. WT mice; #P < 0.05 vs. WT + HFD mice.
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LepRS1138 (n = 9; 34 ± 1.1 g, P < 0.001 vs. WT) and
LepRdb/db mice (n = 7; 40 ± 1.3 g; P < 0.001 vs. WT and
P < 0.01 vs. LepRS1138) to chronic isoprenaline infusion
(20 mg/kg BW per day) was examined. Under basal condi-
tions, similar findings as those in 7 months-old mice were
observed, i.e. LepRS1138 mice exhibited an increased heart
weight (P < 0.05 vs. LepRdb/db; Figure 5A), LV mass (P <
0.01 vs. WT; Figure 5B) and mean WTh (P < 0.05 vs. WT;
Figure 5C), whereas other changes, such as differences in
fractional shortening (Figure 5D), ESD (Figure 5E) and
EDD (Figure 5F) were not (yet) detected. On the other
hand, all mouse groups responded to chronic β-adrenergic
stimulation with significant cardiac hypertrophy, and nodifferences (with the exception of heart weight; Figure 5A)
were observed between LepRS1138 and LepRdb/db mice. Rep-
resentative M-mode echocardiography tracings are shown
in Figure 6 and summarized in Additional file 2: Table S2.
Discussion
The adipocytokine leptin may link obesity with cardiac
hypertrophy, an important risk factor for the develop-
ment of heart failure. Studies in humans [2,3] and ro-
dents [10,11] have shown that obesity is associated with
LV hypertrophy, and body mass index was identified as a
strong and independent predictor of LV mass [2,3]. Im-
portantly, cardiac hypertrophy is also observed in
normotensive obese subjects [6], and plasma leptin levels
Figure 3 Hypertrophic signal transduction in hearts of lean and obese mice. Protein was isolated from hearts of 7 months-old WT (n = 15),
WT + HFD (n = 12), LepRS1138 (n = 15) and LepRdb/db (n = 15) mice and analyzed for the expression of phosphorylated Jak2 (A), Src kinase (B), Akt
(C), PKC (D), p38 (E) and p42/44 MAPK (F). Results are expressed as -fold increase of lean control mice (after normalization for total protein [with
the exception of PKC] and GAPDH expression). The mean ± SEM as well as representative findings are shown. *P < 0.05, **P < 0.01 and ***P <
0.001 vs. WT mice; #P < 0.05 and ##P < 0.01 vs. WT + HFD mice; §P < 0.05, §§P < 0.01 and §§§P < 0.001 for the difference between LepRdb/db and
LepRS1138 mice.
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independent of BW or blood pressure elevations [5],
suggesting a causal role for leptin in the pathogenesis of
cardiac hypertrophy.Although the major source of leptin is adipose tissue,
cardiomyocytes are also capable of synthesizing leptin
[27], and increased cardiac leptin levels have been
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Figure 4 Histological analysis of angiogenesis, apoptosis and fibrosis in hearts of lean and obese mice. Serial cross sections through the
LV of WT, WT + HFD, LepRS1138 and LepRdb/db mice (n = 10 per group) were immunostained and the number of (A) CD31-positive endothelial
cells and (B) TUNEL-positive apoptotic cell nuclei determined. Results are expressed per cardiomyocyte and/or mm2. (C) The degree of cardiac
fibrosis was quantified after Masson’s trichrome (MTC) staining. Results are expressed as % of total tissue area (at 200-fold magnification). The
mean ± SEM as well as representative findings are shown. **P < 0.01 and ***P < 0.001 vs. WT; #P < 0.05, ##P < 0.01 and ###P < 0.001 vs. WT +
HFD mice.
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study, elevated circulating as well as cardiac leptin levels
were detected in both diet-induced and genetically obese
mice, which may have acted on cardiomyocytes as well
as other, non-cardiomyocyte cells expressing leptin re-
ceptors [29]. Although leptin serum levels were higher
than in previous publications [30], we explain this find-
ings with the higher age of the mice, a factor previously
found to be associated with increased circulating leptinlevels [31]. Leptin has been shown to stimulate the hyper-
trophy of cardiomyocytes isolated from rats [7,20] or
humans [8,19]. Moreover, chronic leptin infusion in-
creased cardiac ANP expression after myocardial infarc-
tion (MI) in mice [32], whereas neutralizing LepR
antibodies abrogated the hypertrophy of the surviving
myocardium after coronary artery ligation in rats [33]. On
the other hand and as confirmed in our analysis, cardiac
hypertrophy also develops in leptin- and LepR-deficient
Figure 5 Echocardiography findings in young lean and obese mice before and after chronic β-adrenergic stimulation. Isoprenaline-filled
osmotic minipumps were subcutaneously implanted into 2 months-old WT (n = 12), LepRS1138 (n = 9) and LepRdb/db (n = 7) mice to examine the
cardiac response to a hypertrophic stimulus other than leptin. Echocardiography (A-F) was performed immediately before (open bars) as well as
at the time of tissue harvest 14 days later (dotted bars). *P < 0.05, *P < 0.01 and ***P < 0.001 for differences vs. WT mice; §P < 0.05 for differences
between LepRdb/db and LepRS1138 mice. Significance levels for differences before and after isoprenaline stimulation (as determined using
Student’s t test for paired means) are indicated within the graph.
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oric restriction experiments suggested that the anti-
hypertrophic effects of leptin had occurred in addition to
weight loss [12], which itself may preserve heart function
and attenuate LV remodeling [34]. Thus, it is unclear
whether the cardiac hypertrophy in obesity is the conse-
quence of pro-hypertrophic effects of the adipokine or ra-
ther the result of a resistance towards leptin’s preventive
effects on hypertrophic cardiac remodeling. Of note, since
body weight is markedly elevated in the diet-induced and
particularly, the genetically obese mice, the heart-to-bodyweight ratio decreases, even though the absolute heart
weight is increased (but to a relatively lesser extent).
Obesity is associated with elevated circulating lep-
tin levels and hypothalamic resistance to the weight-
reducing effects of the adipokine, whereas the existence
of a peripheral (e.g. cardiac) leptin resistance is contro-
versial. For example, reduced cardiac LepR expression
has been reported in HFD-fed rats [14], whereas others
demonstrated unaltered cardiac STAT3 phosphorylation
in diet-induced obese rodents following acute leptin ad-
ministration [15-17]. Our findings also suggest that
Figure 6 Representative M-mode echocardiography recordings.
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spond to leptin in the presence of chronically elevated
leptin levels and that the observed elevation of serum
and cardiac leptin may thus contribute to the develop-
ment of cardiac hypertrophy in obesity. For example,
hearts of hyperleptinemic obese WT mice (i.e. those
with intact leptin receptors) exhibited signs of activated
leptin signaling, including elevated levels of phosphory-
lated LepR and STAT3, while they were unchanged or
reduced in mice with mutated or truncated forms ofLepR (i.e. LepRS1138 or LepRdb/db mice). Moreover, both
lean and obese WT mice responded to a single leptin in-
jection with increased cardiac STAT3 phosphorylation.
Of note, we could not spatially dissect the cardiac re-
sponsiveness to leptin, since whole heart homogenates
were examined. Possible explanations underlying the dis-
crepancy between the present and some previous studies
include the animal species, as the absence of a response
to leptin in obesity has been so far primarily observed in
rats [14]. In addition, age, sex and feeding status of the
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may have influenced the results. Of note, previous studies
in humans have reported the existence of individuals (up
to 40%) exhibiting a blunted response to leptin [35], al-
though it is unknown, whether such phenomenon also oc-
curs in rodents.
Interestingly, hearts from LepRS1138 mice exhibited a
marked overactivation of STAT3-independent leptin sig-
naling pathways, including Jak2, Src kinase, Akt or p38
MAPK, i.e. factors previously shown to mediate the pro-
hypertrophic effects of the adipokine in cardiomyocytes
[19,20]. Importantly, overactivation of leptin signaling in
hearts of LepRS1138 mice was accompanied by a pro-
nounced cardiac hypertrophy, both at the organ and the
single cardiomyocyte level, despite similar adiposity. Al-
though leptin levels were found to be lower in LepRS1138
compared to LepRdb/db mice, as previously reported [23],
leptin continues to be able to activate LepR signal trans-
duction in these mice, for example via LepR-Tyr985.
Similar echocardiographical findings were obtained in
young (i.e. 2 months-old) and older (i.e. 7 months-old)
mice, arguing against the development of cardiac hyper-
trophy secondary to hemodynamic or other metabolic
changes associated with obesity, although we cannot ex-
clude the possible contribution of a more pronounced
hyperinsulinemia [23] to the development of cardiac
hypertrophy in LepRS1138 mice. On the other hand,
hypertension had not been observed in ob/ob mice [12],
and heart weight increase and concentric LV hyper-
trophy in obese mice and humans also occurs without
systolic and diastolic blood pressure elevations [5,6,36].
Although a predominant cardiac expression of the short
(i.e. without STAT3 binding site) over the long LepR iso-
form has been reported [7,29], previous studies have
shown that stimulation of neonatal rat cardiomyocytes
with leptin increased STAT3 phosphorylation, nuclear
translocation and DNA binding activity [32]. Also, cardiac
STAT3 activation after MI was blunted in leptin-deficient
mice [13]. The observation that increased cardiac STAT3
phosphorylation in hyperleptinemic, diet-induced obese
mice was reduced or almost completely abolished in
LepRS1138 or LepRdb/db mice suggests that cardiac STAT3
activation in obesity largely occurs downstream of ele-
vated leptin levels and that other cytokines, also elevated
in obesity and known to signal via Jak2-STAT3, may be of
minor importance. On the other hand, the importance of
leptin-mediated STAT3 activation in the heart and its con-
tribution to cardioprotective signaling pathways in vivo
have not been directly examined so far.
STAT3 has been implicated in cardioprotection after
various injuries. For example, cardiomyocyte-specific
STAT3 deletion results in dilatative cardiomyopathy,
characterized by increased apoptosis and interstitial fi-
brosis as well as reduced myocardial capillary density[21,22]. Previous studies suggested that leptin may exert
beneficial effects on the heart. For example, administra-
tion of leptin was associated with smaller infarct size
after ischemia/reperfusion injury [37], whereas ischemic
postconditioning failed to induce cardioprotection
in mice lacking leptin or its receptor [38]. Also, leptin
deficiency was associated with a worsened cardiac func-
tion and survival after coronary artery ligation, which
could be improved by leptin repletion [13]. Regarding
possible mechanisms, increased cardiac myocyte apop-
tosis was observed in hearts from leptin (receptor)-defi-
cient mice [39,40]. Similar findings were obtained
in vitro, showing that leptin protects cardiomyocytes
against apoptotic cell death induced by serum starvation
[41]. Our analyses also revealed significantly elevated
numbers of apoptotic cells in hearts of obese LepRS1138
and LepRdb/db mice, consistent with a reduced activation
of STAT3-responsive anti-apoptotic genes [40]. Although
findings in mice with systemic defects in leptin signal
transduction may have been confounded by the concomi-
tant presence of obesity and associated metabolic and in-
flammatory alterations, adverse cardiac remodeling after
MI [42] or lethal heart failure [43] were recently reported
in mice with cardiomyocyte-specific LepR deletion. On
the other hand, the beneficial effects of leptin-mediated
STAT3 activation may not be restricted to cardiomyo-
cytes. For example, we and others have shown that leptin
promotes the angiogenic properties of endothelial (pro-
genitor) cells [25,44], and cardiac angiogenesis was re-
duced in LepRS1138 and LepRdb/db mice. In addition,
hearts of obese LepRS1138 and LepRdb/db mice exhibited
increased interstitial fibrosis, which may have occurred
secondary to increased cardiomyocyte loss, although pre-
vious studies have shown that leptin may also directly in-
fluence myocardial matrix metabolism [45]. On the
functional level, the enhanced activation of pro-
hypertrophic signaling pathways in the absence of STAT3-
mediated cardioprotection may have contributed to the
echocardiographic finding of LV cavity dilation in
LepRS1138 compared to LepRdb/db mice.Conclusions
Taken together, our findings suggest that hearts from
diet-induced obese mice continue to respond to chronic-
ally elevated leptin levels and that increased systemic
and/or local leptin and enhanced cardiac LepR activation
contribute the development of cardiac hypertrophy. On
the other hand, chronic overactivation of hypertrophic
signaling mediators together with an inabilitity to acti-
vate STAT3-dependent cardioprotective pathways may
promote maladaptive cardiac remodeling. Of note, our
findings also indicate that leptin signaling is not a pre-
requisite to develop cardiac hypertrophy in obesity and
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in LV mass associated with higher body weight.
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